Payment overview · 2025
General Payments
$556.83
32 reported records · 16 companies
Healthcare provider profile · identity verified
Heather Highsmith, MD
Allopathic & Osteopathic Physicians|Family Medicine · GREENWOOD, SC · NPI 1053847889
Verified facts
What the public records show
CMS Open Payments records show Heather Highsmith, MD received $556.83 in general payments during 2025 across 32 reported records.
Amgen Inc. accounted for 24.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $138.13 | 24.8% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $54.11 | 9.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.39 | 8.9% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $37.86 | 6.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $35.10 | 6.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.28 | 6.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $30.63 | 5.5% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $28.21 | 5.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $26.06 | 4.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.39 | 3.7% | 1 | 2025 |
| Kedrion Biopharma, Inc. | Unresolved — no canonical attribution shown | $20.27 | 3.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.07 | 3.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.73 | 3.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.79 | 3.0% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.86 | 2.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.95 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $556.83 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $97.72 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $54.11 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $45.05 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $40.41 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $35.10 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.28 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.18 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $30.63 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $28.21 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $26.06 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $22.63 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| Albuked Normalized: albuked |
Biological | Kedrion Biopharma, Inc. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| GAMMAKED Normalized: gammaked |
Biological | Kedrion Biopharma, Inc. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| KEDRAB Normalized: kedrab |
Biological | Kedrion Biopharma, Inc. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| KOATE Normalized: koate |
Biological | Kedrion Biopharma, Inc. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| RhoGAM Ultra-Filtered PLUS Normalized: rhogam ultra filtered plus |
Biological | Kedrion Biopharma, Inc. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 138 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
138 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 317 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 223 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 198 | 68 |
| Omeprazole | Omeprazole | 154 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 151 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 149 | 46 |
| Losartan Potassium | Losartan Potassium | 143 | 43 |
| Mounjaro | Tirzepatide | 138 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 136 | 46 |
| Metformin Hcl | Metformin Hcl | 113 | 43 |
| Lisinopril | Lisinopril | 112 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 44 |
| Potassium Chloride | Potassium Chloride | 103 | 41 |
| Gabapentin | Gabapentin | 102 | 40 |
| Meloxicam | Meloxicam | 97 | 31 |
| Prednisone | Prednisone | 92 | 80 |
| Tramadol Hcl | Tramadol Hcl | 91 | 23 |
| Alprazolam | Alprazolam | 88 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 29 |
| Famotidine | Famotidine | 82 | 29 |
| Furosemide | Furosemide | 80 | 34 |
| Montelukast Sodium | Montelukast Sodium | 75 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 71 | 30 |
| Sertraline Hcl | Sertraline Hcl | 71 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 19 |
| Carvedilol | Carvedilol | 61 | 20 |
| Pregabalin | Pregabalin | 59 | 16 |
| Jardiance | Empagliflozin | 58 | suppressed |
| Cephalexin | Cephalexin | 53 | 45 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 24 |
| Trazodone Hcl | Trazodone Hcl | 53 | 16 |
| Chlorthalidone | Chlorthalidone | 52 | 15 |
| Eliquis | Apixaban | 52 | 17 |
| Metformin Hcl Er | Metformin Hcl | 51 | 16 |
| Simvastatin | Simvastatin | 51 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 15 |
| Allopurinol | Allopurinol | 49 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 17 |
| Nystatin | Nystatin | 47 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 44 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 40 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 39 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Vraylar | Cariprazine Hcl | 35 | suppressed |
| Rybelsus | Semaglutide | 34 | suppressed |
| Spironolactone | Spironolactone | 33 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | 12 |
| Ibuprofen | Ibuprofen | 31 | 11 |
| Lorazepam | Lorazepam | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 27 |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | 11 |
| Clonazepam | Clonazepam | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | 11 |
| Naproxen | Naproxen | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Cefdinir | Cefdinir | 22 | 21 |
| Fluconazole | Fluconazole | 22 | 17 |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 18 |
| Glipizide Er | Glipizide | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 19 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 14 |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
| Ozempic | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $556.83 · 32 records | Amgen Inc. | AIRSUPRA, AREXVY, Albuked, BEXSERO, Dexcom G6 Transmitter, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), EVENITY, FARXIGA, GAMMAKED, KEDRAB, KOATE, LEQVIO, MOUNJARO, OTEZLA, Ozempic, PROLIA, Qelbree, REPATHA, REXULTI, RhoGAM Ultra-Filtered PLUS, SHINGRIX, The Cologuard Plus Collection Kit, VERQUVO, VRAYLAR, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error